PHARMACOLOGY OF AQUEOUS OUTFLOW IN THE HUMAN EYE

描述（研究者摘要）：拟定的总体目标 研究的目的是获得更多的生理学和药理学知识， 在拟议的研究中，研究人员 我选择了两类药物， 青光眼的治疗;肾上腺素能药物和胆碱能药物。 的 具体目标是表征流出设施对这些药物的反应 在她最近描述的人体孤立流出道灌注模型中， 绘制药物受体在流出组织中的分布， 描述相关的第二信使系统。这种三管齐下 方法，协调生理学，生物化学和分子生物学研究 生物学，有可能产生大量的信息， 而不是单独的方法。 最近的改进 在分子生物学技术及其应用上的革命性进展 疾病的诊断和治疗，以及基础医学研究。 调查人员希望她的方法，利用这种强大的新的 结合人类TM模型的技术将使她能够开发 一个人类外流系统的合成地图， 细胞介导流出阻力的变化，并表征 第二信使系统与这些变化相关。 增强 了解正常流出的基本机制 生理学可能为原发性开角型青光眼的发病机制提供新的见解 青光眼，并可能会促进更有效的发展， 特异性和安全的抗青光眼药物。

DESCRIPTION (Investigator's Abstract): The overall goal of proposed research is to gain further knowledge of the physiology and pharmacology of aqueous outflow in the human eye.In proposed studies, the investigators have chosen to look at two general classes of drugs used therapeutically in the treatment of glaucoma; adrenergic agents and cholinergic agents. The specific aims are to characterize outflow facility responses to these drugs in her recently described human isolated outflow pathway perfusion model, to map the distribution of drug receptors in outflow tissues, and to characterize relevant second messenger systems. This three-pronged approach, coordinating studies in physiology, biochemistry, and molecular biology, has the potential for producing a wealth of information greater than the sum of each individual approach in isolation. Recent refinements in molecular biology techniques and their applications is revolutionizing the diagnosis and treatment of disease, as well as basic medical research. The investigator's hope that her approach, using this powerful new technology in conjunction with the human TM model will allow her to develop a composite map of the human outflow system which will localize groups of cells which mediate changes in outflow resistance and characterize the second messenger systems which are coupled to these changes. Enhanced understanding of the basic mechanism(s) underlying normal outflow physiology may lend new insight into the pathogenesis of primary open angle glaucoma, and probably will facilitate the development of more effective, specific, and safe antiglaucoma drugs.